These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31943236)

  • 21. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
    Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
    Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
    Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Madsen LW; Christensen PB; Fahnøe U; Pedersen MS; Bukh J; Øvrehus A
    Liver Int; 2021 Nov; 41(11):2601-2610. PubMed ID: 34154034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
    Hubbard H; Lawitz E
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
    Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
    Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
    de Salazar A; Dietz J; di Maio VC; Vermehren J; Paolucci S; Müllhaupt B; Coppola N; Cabezas J; Stauber RE; Puoti M; Arenas Ruiz Tapiador JI; Graf C; Aragri M; Jimenez M; Callegaro A; Pascasio Acevedo JM; Macias Rodriguez MA; Rosales Zabal JM; Micheli V; Garcia Del Toro M; Téllez F; García F; Sarrazin C; Ceccherini-Silberstein F;
    J Antimicrob Chemother; 2020 Nov; 75(11):3349-3358. PubMed ID: 32772078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
    Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
    Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2019 Jan; 91(1):102-106. PubMed ID: 30091810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR
    Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
    Gane E; de Ledinghen V; Dylla DE; Rizzardini G; Shiffman ML; Barclay ST; Calleja JL; Xue Z; Burroughs M; Gutierrez JA
    J Viral Hepat; 2021 Nov; 28(11):1635-1642. PubMed ID: 34448313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    Foster GR; Asselah T; Kopecky-Bromberg S; Lei Y; Asatryan A; Trinh R; Zadeikis N; Mensa FJ
    PLoS One; 2019; 14(1):e0208506. PubMed ID: 30601818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.